707 related articles for article (PubMed ID: 28475276)
1. Cytokine Biomarkers of Disease Activity and Therapeutic Response after Initiating Methotrexate Therapy in Patients with Juvenile Idiopathic Arthritis.
Funk RS; Chan MA; Becker ML
Pharmacotherapy; 2017 Jun; 37(6):700-711. PubMed ID: 28475276
[TBL] [Abstract][Full Text] [Related]
2. S100A12 Is Associated with Response to Therapy in Juvenile Idiopathic Arthritis.
Gohar F; Anink J; Moncrieffe H; Van Suijlekom-Smit LWA; Prince FHM; van Rossum MAJ; Dolman KM; Hoppenreijs EPAH; Ten Cate R; Ursu S; Wedderburn LR; Horneff G; Frosch M; Foell D; Holzinger D
J Rheumatol; 2018 Apr; 45(4):547-554. PubMed ID: 29335345
[TBL] [Abstract][Full Text] [Related]
3. Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis.
Swart JF; van Dijkhuizen EHP; Wulffraat NM; de Roock S
Ann Rheum Dis; 2018 Mar; 77(3):336-342. PubMed ID: 29138257
[TBL] [Abstract][Full Text] [Related]
4. Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis.
Khraishi M; Millson B; Woolcott J; Jones H; Marshall L; Ruperto N
Pediatr Rheumatol Online J; 2019 Sep; 17(1):64. PubMed ID: 31500631
[TBL] [Abstract][Full Text] [Related]
5. Proinflammatory cytokines in monitoring the course of disease and effectiveness of treatment with etanercept (ETN) of children with oligo- and polyarticular juvenile idiopathic arthritis (JIA).
Kaminiarczyk-Pyzalka D; Adamczak K; Mikos H; Klimecka I; Moczko J; Niedziela M
Clin Lab; 2014; 60(9):1481-90. PubMed ID: 25291944
[TBL] [Abstract][Full Text] [Related]
6. Treatment response to etanercept in methotrexate refractory juvenile idiopathic arthritis: an analysis of predictors and long-term outcomes.
Su Y; Yang YH; Chiang BL
Clin Rheumatol; 2017 Sep; 36(9):1997-2004. PubMed ID: 28540607
[TBL] [Abstract][Full Text] [Related]
7. The impact of disease activity and tumour necrosis factor-α inhibitor therapy on cytokine levels in juvenile idiopathic arthritis.
Walters HM; Pan N; Lehman TJ; Adams A; Kalliolias GD; Zhu YS; Santiago F; Nguyen J; Sitaras L; Cunningham-Rundles S; Walsh TJ; Toussi SS
Clin Exp Immunol; 2016 Jun; 184(3):308-17. PubMed ID: 26934060
[TBL] [Abstract][Full Text] [Related]
8. Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry.
Beukelman T; Lougee A; Matsouaka RA; Collier D; Rumsey DG; Schenfeld J; Stryker S; Twilt M; Kimura Y;
Pediatr Rheumatol Online J; 2021 Aug; 19(1):131. PubMed ID: 34419107
[TBL] [Abstract][Full Text] [Related]
9. Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study.
Levälampi T; Kärki J; Rebane K; Vähäsalo P; Malin M; Kröger L; Grönlund MM; Backström M; Pohjankoski H; Kautiainen H; Jokiranta S; Aalto K
Pediatr Rheumatol Online J; 2023 Mar; 21(1):27. PubMed ID: 36949461
[TBL] [Abstract][Full Text] [Related]
10. Methotrexate treatment affects effector but not regulatory T cells in juvenile idiopathic arthritis.
Bulatović Ćalasan M; Vastert SJ; Scholman RC; Verweij F; Klein M; Wulffraat NM; Prakken BJ; van Wijk F
Rheumatology (Oxford); 2015 Sep; 54(9):1724-34. PubMed ID: 25877908
[TBL] [Abstract][Full Text] [Related]
11. Etanercept concentration and immunogenicity do not influence the response to Etanercept in patients with juvenile idiopathic arthritis.
Bader-Meunier B; Krzysiek R; Lemelle I; Pajot C; Carbasse A; Poignant S; Melki I; Quartier P; Choupeaux L; Henry E; Treluyer JM; Belot A; Hacein-Bey-Abina S; Urien S
Semin Arthritis Rheum; 2019 Jun; 48(6):1014-1018. PubMed ID: 30396593
[TBL] [Abstract][Full Text] [Related]
12. MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis.
Anink J; Van Suijlekom-Smit LW; Otten MH; Prince FH; van Rossum MA; Dolman KM; Hoppenreijs EP; ten Cate R; Ursu S; Wedderburn LR; Horneff G; Frosch M; Vogl T; Gohar F; Foell D; Roth J; Holzinger D
Arthritis Res Ther; 2015 Aug; 17(1):200. PubMed ID: 26249667
[TBL] [Abstract][Full Text] [Related]
13. Prediction of methotrexate intolerance in juvenile idiopathic arthritis: a prospective, observational cohort study.
van Dijkhuizen EH; Bulatović Ćalasan M; Pluijm SM; de Rotte MC; Vastert SJ; Kamphuis S; de Jonge R; Wulffraat NM
Pediatr Rheumatol Online J; 2015; 13():5. PubMed ID: 25745368
[TBL] [Abstract][Full Text] [Related]
14. Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study.
Davies R; Southwood TR; Kearsley-Fleet L; Lunt M; Hyrich KL;
Arthritis Rheumatol; 2015 Sep; 67(9):2487-94. PubMed ID: 25989609
[TBL] [Abstract][Full Text] [Related]
15. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
Seitz M; Zwicker M; Villiger PM
J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
[TBL] [Abstract][Full Text] [Related]
16. Etanercept improves lipid profile and oxidative stress measures in patients with juvenile idiopathic arthritis.
De Sanctis S; Marcovecchio ML; Gaspari S; Del Torto M; Mohn A; Chiarelli F; Breda L
J Rheumatol; 2013 Jun; 40(6):943-8. PubMed ID: 23547210
[TBL] [Abstract][Full Text] [Related]
17. Relation of interleukin-6, TNF-alpha and interleukin-1alpha with disease activity and severity in juvenile idiopathic arthritis patients.
Spîrchez M; Samaşca G; Iancu M; Bolba C; Miu N
Clin Lab; 2012; 58(3-4):253-60. PubMed ID: 22582498
[TBL] [Abstract][Full Text] [Related]
18. Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis.
Bichler J; Benseler SM; Krumrey-Langkammerer M; Haas JP; Hügle B
Scand J Rheumatol; 2015; 44(4):280-3. PubMed ID: 25993023
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration.
Fráňová J; Fingerhutová Š; Kobrová K; Srp R; Němcová D; Hoza J; Uher M; Saifridová M; Linková L; Doležalová P
Pediatr Rheumatol Online J; 2016 Jun; 14(1):36. PubMed ID: 27301536
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]